New Research From Effective Health Care Program—Stents in CKD
- Many drug-eluting stents (DES) are being placed in patient subsets that were not represented in large, pivotal RCT's.
- New study examines the safety & efficacy of (DES) compared to bare-metal stents (BMS).
- Focuses on "real world," i.e., Medicare-eligible patients over 65 yrs. with chronic kidney disease (CKD).
- Study links American College of Cardiology registry to Centers for Medicare & Medicaid Services (CMS) data.
- Results: In patients with CKD treated with a DES versus BMS, treatment with a DES appeared to be safe with an associated reduction in the rates of MI and death.
Tsai TT et al., J Am Coll Cardiol 2011; 58:1859-1869.
Previous Slide Contents Next Slide